Karyopharm Therapeutics
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $38,783 | $42,786 | $33,125 | $33,747 |
Gross Profit | 37,483 | 41,230 | 31,129 | 32,184 |
EBITDA | -20,576 | 32,899 | -31,322 | -35,422 |
EBIT | -20,659 | 32,808 | -31,407 | -35,499 |
Net Income | -32,072 | 23,792 | -37,362 | -41,837 |
Net Change In Cash | 38,783 | 42,786 | 33,125 | 33,747 |
Free Cash Flow | -19,453 | -38,498 | -43,920 | -18,585 |
Cash | 72,828 | 84,806 | 31,087 | 52,891 |
Basic Shares | 125,010 | 154,425 | 115,454 | 114,778 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $146,033 | $157,074 | $209,819 | $108,085 |
Gross Profit | 141,091 | 151,861 | 206,417 | 105,380 |
EBITDA | -118,423 | -139,305 | -96,985 | -167,852 |
EBIT | -118,953 | -139,926 | -97,774 | -168,824 |
Net Income | -143,099 | -165,291 | -124,088 | -196,273 |
Net Change In Cash | 146,033 | 157,074 | 209,819 | 108,085 |
Cost of Revenue | -60,072 | 108,372 | -41,836 | |
Free Cash Flow | -92,723 | -149,672 | -112,828 | -160,379 |
Cash | 52,231 | 135,188 | 190,459 | 85,918 |
Basic Shares | 114,221 | 81,871 | 75,218 | 72,044 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$0.25 |
2024-06-30 | $0.15 |
2024-03-31 | -$0.32 |
2023-12-31 | -$0.36 |
